论文部分内容阅读
我们将静脉注射用免疫球蛋白 (ＩＶＩＧ)与免疫抑制剂甲氨蝶呤 (ＭＴＸ)在体外交联制成标记抗体 ,使ＭＴＸ通过ＩＶＩＧ特异地与单核巨噬细胞结合 ,对单核 巨噬系统起到杀伤或抑制作用 ,既克服了ＩＶＩＧ疗效短暂的缺点 ,又避免了免疫抑制剂的非特异性细胞毒作用。现将体外实验
We cross-link IVIG with the immunosuppressant methotrexate (MTX) in vitro to create a labeled antibody that binds MTX specifically to mononuclear macrophages via IVIG, System to play a killing or inhibiting effect, both to overcome the shortcomings of IVIG curative effect, but also to avoid the non-specific cytotoxicity of immunosuppressive agents. Now in vitro experiments